ScholarLens Back to search
2010•China Practical MedicineRequires access

Establishment of real time quantitative PCR to test PSMA and alternative spliced variant PSMA5 and exploration the application in the clinical

Hua Zeng

Open publisher page 0 citations

Abstract

Objective Explore the clinical application of PSMA and PSMA5 in the diagnosis of the prostatic carcinoma and prostate hyperplasia.Methods Using the quantitative RT-PCR method built by ourselves to test the PSMA DNA in LNcap cells and the peripheral blood cell of the prostate hyperplasia and prostate tumor patients.Results PSMA DNA in the peripheral blood cells of the prostate hyperplasia and prostate cancer patients were more than those of the normal ones.PSMA5 DNA in the peripheral blood cells of the prostate cancer patients were more than PSMA mRNA.Conclusion The difference of PSMA and PSMA5 DNA in the peripheral blood cells showed that PSMA5 is more specific as a prostate tumor maker.Give us a new research way to use the PSMA as a prostate tumor marker.

About this research paper

What this paper is about

Objective Explore the clinical application of PSMA and PSMA5 in the diagnosis of the prostatic carcinoma and prostate hyperplasia.Methods Using the quantitative RT-PCR method built by ourselves to test the PSMA DNA in LNcap cells and the peripheral blood cell of the prostate hyperplasia and prostate tumor patients.Results PSMA DNA in the peripheral blood cells of the prostate hyperplasia and prostate cancer patients were more than those of the normal ones.PSMA5 DNA in the peripheral blood cells of the prostate cancer patients were more than PSMA mRNA.Conclusion The difference of PSMA and PSMA5 DNA in the peripheral blood cells showed that PSMA5 is more specific as a prostate tumor maker.Give us a new research way to use the PSMA as a prostate tumor marker.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective Explore the clinical application of PSMA and PSMA5 in the diagnosis of the prostatic carcinoma and prostate hyperplasia.Methods Using the quantitative RT-PCR method built by ourselves to test the PSMA DNA in LNcap cells and the peripheral blood cell of the prostate hyperplasia and prostate tumor patients.Results PSMA DNA in the peripheral blood cells of the prostate hyperplasia and prostate cancer patients were more than those of the normal ones.PSMA5 DNA in the peripheral blood cells of the prostate cancer patients were more than PSMA mRNA.Conclusion The difference of PSMA and PSMA5 DNA in the peripheral blood cells showed that PSMA5 is more specific as a prostate tumor maker.Give us a new research way to use the PSMA as a prostate tumor marker.

Key concepts: Medicine, Prostate cancer, LNCaP, PCA3, Hyperplasia, Prostate, Peripheral blood, Circulating tumor cell

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Establishment of real time quantitative PCR to test PSMA and alternative spliced variant PSMA5 and exploration the application in the clinical — Research Paper | ScholarLens